Testing steroids for scarred lung caused by allergy
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether corticosteroid therapy can help people with a type of lung scarring caused by an allergic reaction (hypersensitivity pneumonitis). It compares the steroid to a placebo to see if it improves breathing and lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 89 years old
- You have a diagnosis of fibrotic hypersensitivity pneumonitis (lung scarring from an allergy) confirmed by a team of doctors
- The scarring covers at least 10% of your lungs on a CT scan
- Your lung function is mildly to moderately reduced (not too severe)
- You have not been treated before for this condition with steroids, immune-suppressing drugs, or anti-fibrotic medications
- You are not pregnant or breastfeeding, and you agree to use effective birth control if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies whether glucocorticoid (steroid) medicine helps people with idiopathic pulmonary fibrosis (IPF) who have a sudden flare-up, compared with an inactive placebo. You may be helped if steroids improve breathing and recovery during these acute episodes, but the study is designed to test that clearly.
This study tests an oral medication (H01/hymecromone) to see if it can help people with progressive lung scarring (ILD). It lasts about 12 to 24 weeks and requires good lung function without needing oxygen at rest.
This study tests whether a new drug called nerandomilast can slow down scarring in the lungs for people with certain types of fibrosing interstitial lung disease (a condition where lung tissue becomes thick and scarred). You may qualify if you have lung scarring that is getting worse and haven't tried this or similar drugs before.
This trial tests if a combination of three drugs (azithromycin, hydroxychloroquine, and prednisone) can help people with a genetic form of lung scarring. The goal is to see if these medicines calm the immune system and slow down the disease.
This trial tests a new oral medicine, nerandomilast, to see if it helps children and teens (ages 2 to under 18) who have a type of lung disease that causes scarring (interstitial lung disease). The study monitors how well patients tolerate the drug and whether it improves their breathing.
This trial tests a new medicine called TX000045 for people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug can help improve breathing and daily function.
Hear when a new Hypersensitivity Pneumonitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.